Medartis Shareholders Overwhelmingly Back Board Proposals at AGM 2026

Medartis Holding AG, a leading medical device manufacturer specializing in surgical fixation and joint replacement, announced that its shareholders overwhelmingly approved all Board of Directors' proposals at the Annual General Meeting (AGM) held on April 23, 2026, in Basel, Switzerland. With 77.4% of total share capital represented, the AGM saw strong participation as shareholders voted on key governance and financial matters. All board members standing for re-election received over 93.8% support, and Yang Xu was newly elected to the Board with 99.7% endorsement, joining the Finance and Audit Committee. The meeting approved the 2025 management report and annual financial statements with 99.99% approval, the remuneration report with 91.0% in a consultative vote, and the sustainability report with 99.2% support, underscoring Medartis' commitment to transparent ESG practices.

The AGM also confirmed the maximum total remuneration for the Board and Executive Management, and reappointed Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors. Chairman Marco Gadola will continue to lead the Board, while Jennifer Dean stepped down after two years. Yang Xu's addition brings fresh expertise to the Finance and Audit Committee. The Board now comprises eight members, including familiar faces like Dr. h.c. Thomas Straumann and newly elected Yang Xu. For detailed voting results, please visit this link.

Medartis also outlined upcoming investor events, including an investor day on June 4, 2026, during the FESSH Hand Surgery Congress in Basel, first-half 2026 results on August 18, 2026, and the next AGM on April 22, 2027. As a global provider of innovative implants and instruments, Medartis employs about 1,400 people and operates in over 60 countries. The strong shareholder endorsement reflects confidence in the company's strategic direction and governance, as highlighted in the original release on NEWMEDIAWIRE. This stability is crucial for Medartis as it continues to advance surgical solutions worldwide.